Personalized Medicine Coalition Applauds Data Presentations at IASLC/ESMO ELCC

The Personalized Medicine Coalition (PMC) applauds the substantial number of new studies focusing on targeted approaches to the treatment of lung cancer presented at the second joint European Lung Cancer Conference of the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) in Geneva.

“The number of studies at this year’s European Lung Cancer Conference suggests notable progress in personalized medicine as well as the understanding and treatment of lung cancer, which is the leading cause of cancer deaths in the U.S.,” said Edward Abrahams, president of PMC. “We hope that applying the principles of personalized medicine to lung cancer, as these studies do, will help us better attack this deadly disease.”

The PMC believes that personalized approaches to diseases such as lung cancer offer the best means of understanding, diagnosing, treating and ultimately curing some of the most challenging health conditions.

Topics: biomarker, blood-based cancer test, cancer diagnostics, ESMO, liquid biopsy, Non-Small Cell Lung Cancer, NSCLC, oncology, IASLC, In the News, personalized Medicine Coalition